Dr. Kevin Lachapelle, MD
Claim this profileMcGill University Health Centre
Studies Pararenal Aneurysms
Studies Aortic Aneurysm
4 reported clinical trials
5 drugs studied
Affiliated Hospitals
Clinical Trials Kevin Lachapelle, MD is currently running
Hypothermia During Aortic Surgery
for undefined
Hypothermic circulatory arrest is an important surgical technique, allowing complex aortic surgeries to be performed safely. Hypothermic circulatory arrest provides protection to cerebral and visceral organs, but may result in longer cardiopulmonary bypass times during surgery, increased risks of bleeding, inflammation, and neuronal injury. To manage these consequences, a trend towards warmer core body temperatures during circulatory arrest has emerged. This trial will randomize patients to either mild (32°C) or moderate (26°C) hypothermia during aortic hemiarch surgery to determine if mild hypothermia reduces the length of cardiopulmonary bypass time and other key measures of morbidity and mortality.
Recruiting1 award N/A5 criteria
Single vs Multiple Arterial Grafts
for Heart Disease
The central hypothesis of ROMA:Women is that the use of multiple arterial grafting (MAG) will improve clinical outcomes and quality of life (QOL) compared to single arterial grfating (SAG). The specific aims of ROMA:Women are: Aim 1: Determine the impact of MAG vs SAG on major adverse cardiac and cerebrovascular events in women undergoing coronary artery bypass grfating (CABG). The investigators will compare major adverse cardiac and cerebrovascular events (death, stroke, non-procedural myocardial infarction, repeat revascularization, and hospital readmission for acute coronary syndrome or heart failure) in a cohort of 2,000 women randomized 1:1 to MAG or SAG (690 from the parent ROMA trial + 1,310 from ROMA:Women). Differences by important clinical and surgical subgroups (patients younger or older than 70 years, diabetics, racial and ethnic minorities, on vs off pump CABG, type of arterial grafts used) will also be evaluated. The women enrolled in the ongoing ROMA trial (anticipated to be approximately 690) will be included in ROMA:Women, increasing efficiency and reducing enrollment time. Hypothesis 1.0. MAG will reduce the incidence of major adverse cardiac and cerebrovascular events. Hypothesis 1.1. The improvement with MAG will be consistent across key subgroups. Aim 2: Determine the impact of MAG vs SAG on generic and disease-specific QOL, physical and mental health symptoms in women undergoing CABG. The investigators will compare generic (SF-12, EQ-5D) and disease-specific (Seattle Angina Questionnaire) QOL and physical and mental health symptoms (PROMIS-29) in a sub-cohort of 500 women randomized 1:1 to MAG or SAG (including those enrolled in ROMA:QOL). Differences by important subgroups (as defined above) will also be evaluated. Hypothesis 2.0. MAG will improve generic and disease-specific QOL compared to SAG. Hypothesis 2.1. MAG will improve physical and mental health symptoms compared to SAG. Hypothesis 2.2. The improvement with MAG will be consistent across key subgroups.
Recruiting1 award N/A4 criteria
More about Kevin Lachapelle, MD
Clinical Trial Related7 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Kevin Lachapelle, MD has experience with
- Thoracic Aortic Surgery
- Bentracimab (PB2452)
- Hypothermic Circulatory Arrest
- Multiple Arterial Grafting
- Single Arterial Graft
Breakdown of trials Kevin Lachapelle, MD has run
Pararenal Aneurysms
Aortic Aneurysm
Ascending Aortic Aneurysm
Emergency Surgery
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kevin Lachapelle, MD specialize in?
Kevin Lachapelle, MD focuses on Pararenal Aneurysms and Aortic Aneurysm. In particular, much of their work with Pararenal Aneurysms has involved treating patients, or patients who are undergoing treatment.
Is Kevin Lachapelle, MD currently recruiting for clinical trials?
Yes, Kevin Lachapelle, MD is currently recruiting for 3 clinical trials in Montréal Quebec. If you're interested in participating, you should apply.
Are there any treatments that Kevin Lachapelle, MD has studied deeply?
Yes, Kevin Lachapelle, MD has studied treatments such as Thoracic Aortic Surgery, Bentracimab (PB2452), Hypothermic circulatory arrest.
What is the best way to schedule an appointment with Kevin Lachapelle, MD?
Apply for one of the trials that Kevin Lachapelle, MD is conducting.
What is the office address of Kevin Lachapelle, MD?
The office of Kevin Lachapelle, MD is located at: McGill University Health Centre, Montréal, Quebec H3H2R9 Canada. This is the address for their practice at the McGill University Health Centre.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.